| Lenvatinib plus pembrolizumab for advanced endometrial cancer V Makker, N Colombo, A Casado Herráez, AD Santin, E Colomba, ... New England Journal of Medicine 386 (5), 437-448, 2022 | 462 | 2022 |
| Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial V Makker, D Rasco, NJ Vogelzang, MS Brose, AL Cohn, J Mier, ... The Lancet Oncology 20 (5), 711-718, 2019 | 435 | 2019 |
| Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer V Makker, MH Taylor, C Aghajanian, A Oaknin, J Mier, AL Cohn, ... Journal of clinical oncology 38 (26), 2981-2992, 2020 | 433 | 2020 |
| Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors MH Taylor, CH Lee, V Makker, D Rasco, CE Dutcus, J Wu, DE Stepan, ... Journal of Clinical Oncology 38 (11), 1154, 2020 | 349 | 2020 |
| Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ... Annals of oncology 33 (9), 860-877, 2022 | 206 | 2022 |
| Endometrial cancer V Makker, H MacKay, I Ray-Coquard, DA Levine, SN Westin, D Aoki, ... Nature Reviews Disease Primers 7 (1), 88, 2021 | 197 | 2021 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 176 | 2020 |
| A review of immune checkpoint blockade therapy in endometrial cancer AK Green, J Feinberg, V Makker American Society of Clinical Oncology Educational Book 40, 238-244, 2020 | 129 | 2020 |
| Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study GF Fleming, VL Filiaci, B Marzullo, RJ Zaino, SA Davidson, M Pearl, ... Gynecologic oncology 132 (3), 585-592, 2014 | 127 | 2014 |
| Clinical utility of prospective molecular characterization in advanced endometrial cancer TE Soumerai, MTA Donoghue, C Bandlamudi, P Srinivasan, MT Chang, ... Clinical Cancer Research 24 (23), 5939-5947, 2018 | 123 | 2018 |
| Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI … KL Jhaveri, XV Wang, V Makker, SW Luoh, EP Mitchell, JA Zwiebel, ... Annals of Oncology 30 (11), 1821-1830, 2019 | 117 | 2019 |
| Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping MB Schiavone, O Zivanovic, Q Zhou, MM Leitao, DA Levine, RA Soslow, ... Annals of surgical oncology 23, 196-202, 2016 | 109 | 2016 |
| Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer RN Grisham, BE Sylvester, H Won, G McDermott, D DeLair, R Ramirez, ... Journal of clinical oncology 33 (34), 4099, 2015 | 100 | 2015 |
| Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome DM Hyman, L Bakios, G Gualtiere, C Carr, RN Grisham, V Makker, ... Gynecologic oncology 129 (1), 58-62, 2013 | 98 | 2013 |
| New therapies for advanced, recurrent, and metastatic endometrial cancers V Makker, AK Green, RM Wenham, D Mutch, B Davidson, DS Miller Gynecologic oncology research and practice 4, 1-12, 2017 | 97 | 2017 |
| Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion CH Kim, F Khoury-Collado, EL Barber, RA Soslow, V Makker, ... Gynecologic oncology 131 (3), 714-719, 2013 | 93 | 2013 |
| Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate-and high-risk cervical cancer MR Folkert, KK Shih, NR Abu-Rustum, E Jewell, MA Kollmeier, V Makker, ... Gynecologic oncology 128 (2), 288-293, 2013 | 86 | 2013 |
| A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I–IV uterine carcinosarcoma V Makker, NR Abu-Rustum, KM Alektiar, CA Aghajanian, Q Zhou, ... Gynecologic oncology 111 (2), 249-254, 2008 | 82 | 2008 |
| From burnout to resilience: an update for oncologists K Murali, V Makker, J Lynch, S Banerjee American Society of Clinical Oncology Educational Book 38, 862-872, 2018 | 79 | 2018 |
| Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study O Zivanovic, DS Chi, Q Zhou, A Iasonos, JA Konner, V Makker, ... Journal of Clinical Oncology 39 (23), 2594-2604, 2021 | 74 | 2021 |
